The IMF trims its economic growth forecast again as the U.S.-China trade war continues, Brexit worries linger and inflation remains muted.Economyread more
Citigroup thinks Tesla investors hoping for a post-earnings rally later this week should scrutinize a pair of related financial metrics.Investingread more
Olive branches were extended from both China and the U.S. as the two nations are set to restart face-to-face trade negotiations after a monthlong truce.Marketsread more
Coca-Cola topped Wall Street's expectations for earnings and revenue.Food & Beverageread more
New disclosures show Facebook and Amazon each spent more than $4 million on lobbying activity in the second quarter of 2019.Technologyread more
Boris Johnson, one of the biggest voices in the Brexit movement, wins the Conservative Party leadership race by a 2-1 margin.Europe Politicsread more
Disney can nearly double its earnings by 2024, Morgan Stanley said in a note to clients on Tuesday.Investingread more
Amazon is expected to report its second-quarter earnings on Thursday.Investingread more
The largest residential brokerage company in the U.S. is partnering with the largest online retailer in a strategy to boost sales for both.Real Estateread more
Here are the biggest calls on Wall Street on TuesdayInvestingread more
Canaccord Genuity's Tony Dwyer believes stocks are about to fall as much as 5% from their all-time highs.Trading Nationread more
Dr. J. Craig Venter, one of the first scientists to sequence the human genome and the co-founder of biotech firm Human Longevity, describes the next frontier of DNA-driven research and how it will revolutionize the health care industry.
The scientist describes a new examination using DNA testing that uncovered cancer in patients long before it would have shown up using current methods.
"We are learning that we are DNA-software driven species, and that your software determines everything about your life, including how long you are going to live," said Venter.
By analyzing people's genetic code, the scientist hopes to find new pharmaceutical procedures that could predict and even cure some of today's most devastating diseases.
CNBC PRO subscribers have access to this exclusive interview, which was originally broadcast on "Squawk Box. "